#82 – ID Literature Year in Review (LIVE from MAD-ID)
Breakpoints
00:00
Laetermivir Versus Valgand Cyclovir for Prevention of CMV Disease in High Risk Kidney Transplant Patients
The study was looking at Laetermivir versus Valgand cyclovir for the prevention of CMV disease in high risk kidney transplant patients. So this is where your donor is CMV positive and you as the transplant recipient are CMV negative. That makes you very high risk for developing disease. And they looked at the primary endpoint ofCMV disease through 28 weeks and then at a year so this is the 52 week mark and there was no difference. This held true for all pre-specified subgroups including patients that got lymphocyte depleting induction with either camp path or thymo. To me to Erin, these are practice changing data. We will talk ourselves in circles
Transcript
Play full episode
